Browse
S-Space
College of Medicine/School of Medicine (의과대학/대학원)
Dept. of Medicine (의학과)
Journal Papers (저널논문_의학과)
Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Noe Kyeong | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kim, Dong-Wam | - |
dc.contributor.author | Lee, Moon H. | - |
dc.contributor.author | Jung, Chul W. | - |
dc.contributor.author | Cho, Eun K. | - |
dc.contributor.author | Lee, Jong T. | - |
dc.contributor.author | Ahn, Jin S. | - |
dc.contributor.author | Heo, Dae S. | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.date.accessioned | 2020-04-27T11:47:53Z | - |
dc.date.available | 2020-04-27T11:47:53Z | - |
dc.date.created | 2020-04-08 | - |
dc.date.created | 2020-04-08 | - |
dc.date.issued | 1999-10 | - |
dc.identifier.citation | Cancer, Vol.86 No.7, pp.1109-1115 | - |
dc.identifier.issn | 0008-543X | - |
dc.identifier.other | 95333 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165584 | - |
dc.description.abstract | BACKGROUND. SKI-2053 R (SK Chemicals; Kyungki-Do, South Korea) is a new platinum derivative with antitumor activity against various cell lines, including cisplatin-resistant tumor cell lines. Preclinical studies have suggested that it is less nephrotoxic than cisplatin. This study evaluated the efficacy and toxicity of SKI-2053R in the treatment of patients with advanced gastric adenocarcinoma. METHODS. Thirty-seven patients with advanced gastric adenocarcinoma that was unresectable or metastatic were treated. No prior chemotherapy or radiotherapy was allowed. Patients received SKI-2053R 360 mg/m(2) by 1-hour infusion on Day. After the first cycle, subsequent doses were adjusted according to the toxicity. Courses were repeated every 28 days. RESULTS. Thirty-five patients were evaluable for response and toxicity. Six patients achieved a major response (17%; 95% confidence interval, 8-33%); 2 were complete and 4 were partial responses. The median duration of response was 7.2 months, with a range of 1-20 months. Patients could tolerate the treatment without significant toxicity. No patients had Grade 3 or 4 toxicity. The most frequent toxicity was Grade 1 or 2 proteinuria (26% of cycles), but it was mild and transient. Leukopenia, thrombocytopenia, azotemia, nausea and vomiting, and neurotoxicity were not frequent. These low toxicity profiles indicated that the dose of SKI-2053R could be increased in future studies. CONCLUSIONS. SKI-2053R was active in the treatment of patients with gastric adenocarcinoma and had favorable toxicity profiles. Cancel 1999;86:1109-15. (C) 1999 American Cancer Society. | - |
dc.language | 영어 | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1002/(SICI)1097-0142(19991001)86:7<1109::AID-CNCR3>3.0.CO;2-G | - |
dc.citation.journaltitle | Cancer | - |
dc.identifier.wosid | 000082749200003 | - |
dc.identifier.scopusid | 2-s2.0-0033214158 | - |
dc.citation.endpage | 1115 | - |
dc.citation.number | 7 | - |
dc.citation.startpage | 1109 | - |
dc.citation.volume | 86 | - |
dc.identifier.sci | 000082749200003 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Noe Kyeong | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wam | - |
dc.contributor.affiliatedAuthor | Heo, Dae S. | - |
dc.contributor.affiliatedAuthor | Bang, Yung-Jue | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | CARBOPLATIN | - |
dc.subject.keywordPlus | MITOMYCIN | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordAuthor | SKI-2053R | - |
dc.subject.keywordAuthor | gastric carcinoma | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | clinical trial | - |
dc.subject.keywordAuthor | Phase II study | - |
- Appears in Collections:
- College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Journal Papers (저널논문_의학과)
- Files in This Item: There are no files associated with this item.
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.